Boulder, Colorado – March 3, 2006 - Bolder BioTechnology, Inc. is pleased to announce that it has relocated its research operations and corporate headquarters to 2945 Wilderness Place, Suite 100, Boulder, Colorado 80301. The Boulder facility includes approximately 8,500 square feet of laboratory and office space. CRESA Partners of Denver, Colorado provided brokerage services and advised Bolder BioTechnology in the lease transaction.
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at www.bolderbio.com.
CRESA Partners is an international corporate real estate advisory firm exclusively serving space users. CRESA Partners specializes in tenant representation, portfolio administration, project management and capital markets expertise. Worldwide, the firm provides service in 35 countries and more than 125 cities -- including 45 North American CRESA Partners locations. In 2002, CRESA Partners’ North American assignments totaled approximately 35 million square feet valued at nearly $4 billion.
Bolder BioTechnology, Inc: Joe Cox, Ph.D., President (Tel: 303-420-4420)
CRESA Partners-Denver, Inc.: Marc H. Lunde, Managing Partner, Charlie Lutz, Director of Corporate Development, Linda Durham, Senior Transaction Manager (Tel: 303-228-0800)